SAN BRUNO, Calif. & SHANGHAI--(BUSINESS WIRE)--LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs. The new compound, designated LT-673, is in preclinical development as a potential cancer therapeutic.
